The terminology and classification of platelet-rich fibrin (PRF), probably the most commonly used platelet concentrates in regenerative dentistry, are changing as the preparation protocol is modified. Therefore, the basic concepts behind PRF terminology and classification should be updated with consensus.

For many drugs, one product has several names, such as generic, chemical, and brand names. In the United States, the generic name is assigned by the United States Adopted Names Council [1]. A brand name is created by the company requesting approval for the drug and identifies the drug as the exclusive property of that company. Doctors often use the brand name when preparing prescriptions because it is easier to remember and doctors typically learn about new drugs via their brand names. Nevertheless, government officials, doctors, researchers, and others who write about the new compound use the drug’s generic name because it refers to the drug itself and not to a specific company’s claim on the drug or specific product.

Terminology is also important for biologics. Platelet-rich plasma (PRP) has been used routinely for functional tests of platelet aggregation and recently for surgical operations as a biologic. Since Marx first demonstrated its clinical applicability in skeletal tissue regeneration [2], many derivatives prepared by modified protocols have been developed. The basic characteristics of PRP and PRF and their representative derivatives are summarized in Table 1.

Regardless of its variations, “PRP” has served as a “generic name” to date. In addition, because “PRP” accurately represents this compound’s actual contents, it can also be considered as a “chemical name.” Therefore, although PRP is produced not by manufacturers but by individual clinics as necessary, “PRP” can be considered both a “generic” and “chemical name” in the field of pharmaceutical products. To our knowledge, there have been no objections to this terminology [3].

In contrast, the background of PRF development appears somewhat complicated. PRF can be identified as a second-generation, i.e., derivative, of PRP [4]; however, to achieve a more comprehensive understanding, it would be useful to distinguish PRF from other platelet concentrates prepared in the presence of anticoagulants. PRF was developed using an innovative concept without either anticoagulants or coagulation factors. At the time, PRF was designated as L-PRF (leukocyte- and platelet-rich fibrin) and the preparation protocol has been modified later by the developer of PRF, Choukroun [4], to produce advanced PRF (A-PRF) and injectable PRF (i-PRF) as well as several other groups of products (Table 1). To our knowledge, most of these brand names are protected as trademarks.

Ironically, however, these efforts aimed at improvement have made “PRF” a generic name of a fibrin matrix enriched with platelets prepared without exogenous coagulation factors, as the group of the above-mentioned PRF derivatives has become widely used worldwide. Although blood cell contents can be modified by changing the centrifugation speed [5], these products share the same principle of preparation through activation of the intrinsic coagulation cascade. In fact, our previous findings demonstrated that the mechanical and degradation properties of the self-clotted A-PRF membranes are significantly different from those for the exogenous thrombin-clotted platelet-poor fibrin gel membranes, but not self-clotted concentrated growth factors (CGF) membranes.
Therefore, particularly when compared with thrombin-clotted fibrin matrices and according to the custom of drug terminology, it is generally preferred to express self-clotted fibrin matrices by their generic name “PRF” rather than their individual brand names. However, for comparative studies of several PRF derivatives, individual brand names would be useful for precise identification.

In academia, based on search strategies and terms used, many systematic reviews may have analyzed data obtained not only for genuine PRF (Table 1), but also for PRF derivatives [7–9]. Accordingly, the situation around PRF is changeable and likely changing. Even after improvements in growth factor levels and/or architectures, minor modifications in preparation protocols [5] may not substantially overcome possible individual differences.

As another example related to commercial activity for PRF analogs and derivatives, CGF developed by Sacco [10] is the compound with a major market share in Japan. The distributor of the Medifuge centrifuge (specified for CGF preparation) recommends that clinicians use the term “CGF,” but significant numbers of CGF users use the term “PRF” in their conference presentations and research articles. The major reasons for this “replacement” in Japan may be the worldwide popularity and general recognition of PRF, as well as the mismatch of the name “CGF” with its concept/image. Therefore, many users consciously or subconsciously accept “PRF” as a generic name [3].

Finally, we again propose that investigators reach a consensus regarding the terminology and classification of “PRF,” which would be beneficial for further expansion of this therapeutic field. Rather than relying on initial concepts and/or commercial backgrounds, scientists should be flexible and revise terminology and classification as needed.

Table 1
Classification of platelet concentrates.

| Category          | Family (generic name) | Principle of preparation and specific materials or procedures required | Subfamily | Individual (brand name) | Vender | Comments |
|-------------------|-----------------------|---------------------------------------------------------------------|-----------|-------------------------|--------|----------|
| Platelet concentrate | PRP                   | Exogenous coagulation factor-dependent matrix formation            | Home-made type | Single-spin method       | Harvest |          |
|                   |                       | - Whole blood samples collected with exogenous anticoagulants       | Machine (kit)-made type | Double-spin method       |        |          |
|                   |                       | - Exogenous coagulation factors (e.g., thrombin, Ca^{2+})          |           | SmartPrep 2             |        |          |
| PRF               |                       | Glass surface-dependent matrix formation through activation of     | Choukroun's PRF | L-PRF                   | Intra-Lock | Genuine centrifugation and blood collection tubes should be used |
|                   |                       | intrinsic coagulation pathway                                      |           | P-PRF                   | Intra-Lock | As above |
|                   |                       | - Whole blood samples collected without exogenous anticoagulants   |           | A-PRF                   | Process for PRF | As above |
|                   |                       | - Glass tubes                                                      |           | I-PRF                   | Process for PRF | As above |
|                   |                       | - Immediate centrifugation                                          | Sacco's PRF | CGF                     | Silfradent srl | FIBRINET   |
|                   |                       | - Endogenous coagulation factors and intrinsic coagulation pathway | Other machine-made types | PRF/M                   |        |          |
|                   |                       |                                                                     |           | Vivostat PRF            | Vivostat | Depending on Choukroun's protocol but using machines/products made by third parties |

Family names are given in accordance with the principle of preparation protocols and/or representative characteristics. Individual names are commercial names and typically protected by trademark.

Conflict of interest

The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.

References

[1] D.E. Smith Marsh, Overview of generic drugs and drug naming, https://www.merckmanuals.com/home/drugs/brand-name-and-generic-drugs/overview-of-generic-drugs-and-drug-naming [Accessed on 23 August 2017].
[2] Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638–46.
[3] Kawase T. Platelet-rich plasma and its derivatives as promising bioactive materials for regenerative medicine: basic principles and concepts underlying recent advances. Odontolgy 2015;103:126–35.
[4] Dohan DM, Choukroun J, Diss A, Dohan SL, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:e37–44.
[5] Peck M, Hess D, Stephen L. Factors affecting the preparation, constituents, and clinical efficacy of leukocyte-and platelet-rich fibrin (L-PRF). South Afr Dent J 2016;71:298–302.
[6] Iseke K, Watanabe T, Kawabata H, Kitamura Y, Okudera T, Okudera H, et al. Mechanical and degradation properties of advanced platelet-rich fibrin (A-PRF), concentrated growth factors (CGF), and platelet-poor plasma-derived fibrin (PPTF). Int J Implant Dent 2017;3:17.
[7] Miron RJ, Zucchelli G, Pikos MA, Salama M, Lee S, Guillemette V, et al. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. Clin Oral Invest 2017;21:1913–27.
[8] Canellas J, Ritto FG, Medeiros PJD. Evaluation of postoperative complications after mandibular third molar surgery with the use of platelet-rich fibrin: a systematic review and meta-analysis. Int J Oral Maxillofac Surg 2017;46:1138–46.
[9] De Pascale MR, Sommese L, Casamassimi A, Nagoli C. Platelet derivatives in regenerative medicine: an update. Transfus Med Rev 2015;29:52–61.
[10] Corigliano M, Sacco L, Edoardo B. CGF - una proposta terapeutica per la medicina rigenerativa. Odontostoria 2010;1:69–81.